Support the news

Daily Rounds: Board Pay Reconsidered; Disappearing Pepcid; Humanized Mouse; New Lupus Drug

2 more health insurers rethink fees for boards - The Boston Globe "Health insurers Harvard Pilgrim Health Care and Tufts Health Plan said yesterday that their board members will meet later this month to discuss whether to bow to state Attorney General Martha Coakley’s wishes and stop taking five-figure annual payments." (boston.com)

The Case of the Missing Pepcid Tablets - NYTimes.com "The curious disappearance of Pepcid Complete comes as Johnson & Johnson is trying to rectify manufacturing problems at its McNeil Consumer Healthcare unit that have resulted in product recalls dating to September 2009; McNeil provides manufacturing services for the joint venture with Merck that markets Pepcid. But the dearth of Pepcid Complete — like the recent supply interruption of o.b. tampons, another popular consumer product from Johnson & Johnson — illustrates the company’s continuing communication problems with consumers. (The tampons are now back at some retailers, according to the product’s Web site.)" (prescriptions.blogs.nytimes.com)

Local Student Wins Prize For ‘Humanized’ Mouse | WBUR "Alice Chen is a doctoral candidate in a joint program in biomedical engineering at Harvard and MIT. On Wednesday, she was named the winner of this year’s Lemelson-MIT Student Prize for developing a humanized mouse with a tissue-engineered liver. "(WBUR | 90.9 FM)

F.D.A. Approves New Lupus Drug - NYTimes.com "The first new drug to treat lupus in more than half a century won approval from the Food and Drug Administration Wednesday, offering a new option for people with the often debilitating immune system disease. The drug, Benlysta, was developed by Human Genome Sciences and will be marketed by that company and GlaxoSmithKline." (prescriptions.blogs.nytimes.com)

This program aired on March 10, 2011. The audio for this program is not available.

+Join the discussion
TwitterfacebookEmail

Support the news